Loading clinical trials...
Loading clinical trials...
A Phase 2 Study of ANC-501 in the Treatment of Adults With Major Depressive Disorder
Conditions
Interventions
ANC-501
Locations
8
United States
ATP Clinical Research
Orange, California, United States
Florida Behavioral Medicine
Largo, Florida, United States
Innovative Clinical Research, Inc.
Lauderhill, Florida, United States
Combined Research Orlando
Orlando, Florida, United States
Clinilabs Drug Development Corporation
Eatontown, New Jersey, United States
Clinilabs Drug development Corporation
New York, New York, United States
Start Date
September 19, 2022
Primary Completion Date
August 14, 2023
Completion Date
October 18, 2023
Last Updated
December 31, 2024
NCT07226661
NCT07115329
NCT06793397
NCT07025720
NCT06132581
NCT06804525
Lead Sponsor
Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions